Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma

Locally advanced non-small cell lung cancer (LA-NSCLC) presents unique challenges due to its progression and tumor heterogeneity. The effectiveness of consolidation therapies, particularly in patients with gene mutations, remains an area of active investigation.